Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patupilone in Advanced NSCLC
NCT00171834Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2003
- Primary completion
- Sep 2008
- Modality
- Covalent Small Molecules, RNA-Targeting Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patupilone in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoints: Dose-limiting Toxicity and Overall Response Rate. Started Aug 2003; status: completed.
02
Drugs
patupilone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00171834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171834.